Stay updated with breaking news from Robertj Fox. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Issuer: Immunic, Inc. / Key word(s): Scientific publication/Study results Immunic Announces Publication of Data From Its Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting
NEW YORK, June 15, 2022 /PRNewswire/ -- Immunic, Inc. , a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic... | June 15, 2022
A B-cell count of at least 40/µL is necessary to mount an adequate antibody response to COVID-19 boosters in patients with multiple sclerosis, new research shows.
NIH-funded trial offers hope for disease with limited treatment options
DGAP-News: Immunic, Inc. to Participate in Scientific, Investor and Industry Conferences in April vom 13.04.2021, 12:30 Uhr Bild: pixabay.com Immunic, Inc. to Participate in Scientific, Investor and Industry Conferences in April 13.04.2021 / 12:30 Immunic, Inc. to Participate in Scientific, Investor and Industry Conferences in April NEW YORK, April 13, 2021 - Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced participation in t...